TOPICAL ADMINISTRATION OF DANAZOL

• US 20080153789A1
• Filed: 12/26/2007
• Published: 06/26/2008
• Est. Priority Date: 12/26/2006
• Status: Abandoned Application

• Current Assignee: Femmepharma Holding Company Incorporated
• Original Assignee: Femmepharma Holding Company Incorporated
• Inventors: DiPiano, Gerianne T., Dmowski, Paul
• Application Number:
  US11/964,357
• Publication Number:
  US 20080153789A1
• Time in Patent Office: Days
• US Class Current: 514/171
• CPC Class Codes: A61K 2800/782 Enzyme inhibitors; Enzyme antagonists
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 8/63 Steroids; Derivatives thereof
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/06 for countering cellulitis

Abstract

Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty tissue, in particular in cases of cellulite, are disclosed herein. In a preferred embodiment, the drug is danazol or gastrinone. In another embodiment, the drug is danazol in combination with an aromatase inhibitor or an estrogen compound. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion, ointment, gel or emulsion, solution or foam.

Claims

1. A formulation comprising a testosterone analog or gonadotrophin releasing hormone analog in a topical carrier for administration of an effective amount to the skin at an area containing disturbed subcutaneous connective fatty tissue.

2. The formulation of claim 1, where the analog is selected from the group consisting of Gestagens, oestroprogestogens, progestogens, clomiphene citrata, and GnRH analogs with a depot action.

3. The formulation of claim 1 wherein the analog is a testosterone analog.

4. The formulation of claim 3 wherein the analog is danazol.

5. The formulation of claim 4 further comprising an aromatase inhibitor, an anti-estrogen, or progesterone-receptor antagonist.

6. The product of claim 5, further comprising an aromatase inhibitor.

7. The product of claim 6, further comprising an anti-estrogen.

8. The product of claim 1, which is formulated as an ointment, cream, gel, emulsion or lotion.

9. The product of claim 1, further comprising a skin penetration enhancer.

10. A method for decreasing the amount or appearance of subcutaneous connective fatty tissue comprising applying to the skin at the site of the fatty tissue an effective amount of the formulation of claim 1.